Spyre Therapeutics, Inc. · NASDAQ:SYRE
Sloan Sheldon sold 7,958 Spyre Therapeutics, Inc. shares (Form 4)
Traded Apr 1, 2026 · Filed Apr 3, 2026
On Apr 1, 2026, Sloan Sheldon (Chief Medical Officer) sold 7,958 Spyre Therapeutics, Inc. shares at US$50.00 for US$398K under a trading plan, leaving 0 shares. Filed Apr 3, 2026 (Form 4).
- Sold
- 7,958 shares
- Price
- US$50.00
- Value
- US$398K
- Holding after
- 0 shares
- Trading plan
- Yes (Made under a plan set in advance)
- Role
- Chief Medical Officer
The filing in full
| Date | Security | Transaction | Shares | Price | Holding after | Ownership |
|---|---|---|---|---|---|---|
| Apr 1, 2026 | Common Stock | Option exercise | 7,958 | US$21.66 | 7,958 | Direct |
| Apr 1, 2026 | Common Stock | Sale | 7,958 | US$50.00 | 0 | Direct |
Source
Related
- Spyre Therapeutics, Inc.
- Sloan Sheldon
- Spyre Therapeutics, Inc. shareholders
- Form 4 · Sloan Sheldon · Jul 2, 2026
- Form 4 · Sloan Sheldon · Jun 3, 2026
- Form 4 · Sloan Sheldon · May 1, 2026
- Schedule 13D/A · Harwin Peter Evan · Oct 9, 2026
- Form 4 · Burrows Scott L · Oct 2, 2026
- Form 4 · King-Jones Heidy · Oct 2, 2026
- Form 4 · Turtle Cameron · Oct 2, 2026
- Schedule 13G · Paradigm Biocapital Advisors LP · Oct 1, 2026